Gameto Highlights Late-Stage Fertility Program, ARPA-H–Backed Menopause Therapy, and $127 Million in Funding

Gameto has shared an update. The company highlighted a media profile featuring CEO and Co-Founder Dina Radenkovic Turner and Chief Scientific Officer Christian Kramme, which details progress across its women’s health pipeline and funding milestones. Gameto reported that Fertilo, its platform aimed at making IVF faster and more accessible, is in final Phase 3 trials, has contributed to nine births, and has received several regulatory approvals. The company also noted Ameno, a next-generation cell therapy for menopause supported by a $10 million ARPA-H grant and preparing to enter clinical trials, and Deovo, a program focused on advancing research and drug testing for ovarian disease. In addition, Gameto referenced its Series C financing led by Kristina Simmons of Overwater Ventures, bringing total funding to $127 million.

For investors, the update underscores Gameto’s transition from development to late-stage validation in key programs, particularly Fertilo, where Phase 3 status and early regulatory approvals suggest a clearer path toward potential commercialization in the IVF market. The ARPA-H grant backing Ameno reduces early development risk and signals non-dilutive support for its menopause therapy, while Deovo points to additional optionality in ovarian disease research and platform-based drug testing. The disclosed $127 million in cumulative funding and a completed Series C round indicate continued investor confidence and provide capital to advance multiple assets in parallel. If clinical outcomes and regulatory progress continue as indicated, Gameto could strengthen its position within the emerging biopharma category focused on women’s reproductive health, with potential for future revenue streams from fertility treatments, menopause therapies, and research partnerships, though timelines and ultimate market adoption remain contingent on trial results and regulatory decisions.